Editas Medicine (EDIT) & NewLink Genetics (NASDAQ:NLNK) Head-To-Head Survey – registrarjournal.com
|
Editas Medicine (EDIT) & NewLink Genetics (NASDAQ:NLNK) Head-To-Head Survey
registrarjournal.com It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 … |
